The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome
Open accessAbstract
BACKGROUND: The vasoconstrictor terlipressin is used for type 1 hepatorenal syndrome (HRS-1) in many parts of the world and is part of the clinical practice guidelines in Europe. METHODS: We conducted a phase 3 trial to confirm the efficacy and safety of terlipressin plus albumin in adults with HRS-1. The patients were randomly assigned in a 2:1 ratio to receive terlipressin or placebo for up to 14 days; in both groups, concomitant use of albumin was strongly recommended. The primary end point was verified reversal of HRS, defined as two consecutive serum creatinine measurements of 1.5 mg per deciliter or less at least 2 hours apart and survival without renal-replacement therapy for at least 10 days after the completion of treatment. Four prespecified secondary end points were analyzed with the Hochberg procedure to account for multiple comparisons. RESULTS: A total of 300 patients underwent randomization - 199 were assigned to the terlipressin group and 101 to the placebo group. Verified reversal of HRS was reported in 63 patients (32%) in the terlipressin group and 17 patients (17%) in the placebo group (P = 0.006). With respect to the prespecified secondary end points, HRS reversal, defined as any serum creatinine level of 1.5 mg per deciliter or less during the first 14 days, was reported in 78 patients (39%) in the terlipressin group and 18 (18%) in the placebo group (P<0.001); HRS reversal without renal-replacement therapy by day 30, in 68 (34%) and 17 (17%), respectively (P = 0.001); HRS reversal among patients with systemic inflammatory response syndrome (84 patients in the terlipressin group and 48 patients in the placebo group), in 31 (37%) and 3 (6%), respectively (P<0.001); and verified reversal of HRS without recurrence by day 30, in 52 (26%) and 17 (17%), respectively (P = 0.08). At day 90, liver transplantations had been performed in 46 patients (23%) in the terlipressin group and 29 patients (29%) in the placebo group, and death occurred in 101 (51%) and 45 (45%), respectively. More adverse events, including abdominal pain, nausea, diarrhea, and respiratory failure, occurred with terlipressin than with placebo. Death within 90 days due to respiratory disorders occurred in 22 patients (11%) in the terlipressin group and 2 patients (2%) in the placebo group. CONCLUSIONS: In this trial involving adults with cirrhosis and HRS-1, terlipressin was more effective than placebo in improving renal function but was associated with serious adverse events, including respiratory failure. (Funded by Mallinckrodt Pharmaceuticals; CONFIRM ClinicalTrials.gov number, NCT02770716.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
Angeli, P., Bernardi, M., Villanueva, C., Francoz, C., Mookerjee, R. P., Trebicka, J., Krag, A., Laleman, W., & Gines, P. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.024 · Cited by 2,905
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis
Salerno, F., Gerbes, A., Ginès, P., Wong, F., & Arroyo, V. (2008) · Postgraduate Medical Journal · doi:10.1136/gut.2006.107789 · Cited by 1,081
Self-citationAngeli, P., Ginès, P., Wong, F., Bernardi, M., Boyer, T. D., Gerbes, A., Moreau, R., Jalan, R., Sarin, S. K., Piano, S., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.029 · Cited by 863
Self-citationGomez, H., Ince, C., De Backer, D., Pickkers, P., Payen, D., Hotchkiss, J., & Kellum, J. A. (2014) · Shock · doi:10.1097/shk.0000000000000052 · Cited by 783
Sanyal, A. J., Boyer, T., Garcia–Tsao, G., Regenstein, F., Rossaro, L., Appenrodt, B., Blei, A., Gülberg, V., Sigal, S., & Teuber, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.014 · Cited by 663
Self-citationMartín–Llahí, M., Pépin, M., Guevara, M., Díaz, F., Torre, A., Monescillo, A., Soriano, G., Terra, C., Fábrega, E., Arroyo, V., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.024 · Cited by 601
Cavallin, M., Kamath, P. S., Merli, M., Fasolato, S., Toniutto, P., Salerno, F., Bernardi, M., Romanelli, R. G., Colletta, C., Salinas, F., et al. (2015) · Hepatology · doi:10.1002/hep.27709 · Cited by 359
Boyer, T. D., Sanyal, A. J., Wong, F., Frederick, R. T., Lake, J. R., O’Leary, J. G., Ganger, D., Jamil, K., Pappas, S. C., Sigal, S. H., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.026 · Cited by 309
Self-citationGinès, P., Solà, E., Angeli, P., Wong, F., Nadim, M. K., & Kamath, P. S. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0022-7 · Cited by 260
Self-citationPrognosis of Patients with Cirrhosis and AKI Who Initiate RRT
Allegretti, A. S., Parada, X. F. V., Eneanya, N. D., Gilligan, H. M., Xu, D., Zhao, S. J., Dienstag, J. L., Chung, R. T., & Thadhani, R. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03610417 · Cited by 160
Facciorusso, A., Chandar, A. K., Murad, M. H., Prokop, L. J., Muscatiello, N., Kamath, P. S., & Singh, S. (2016) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30157-1 · Cited by 145
Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis
Narahara, Y., Kanazawa, H., Taki, Y., Kimura, Y., Atsukawa, M., Katakura, T., Kidokoro, H., Harimoto, H., Fukuda, T., Matsushita, Y., et al. (2009) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2009.05873.x · Cited by 112
Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis
Rodríguez, E., Elia, C., Solà, E., Barreto, R., Graupera, I., Andrealli, A., Pereira, G., Poca, M., Sánchez‐Delgado, J., Guevara, M., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.032 · Cited by 109
Sanyal, A. J., BOYER, T. D., Frederick, R. T., Wong, F. S.-H., Rossaro, L., Araya, V. R., Vargas, H. E., Reddy, K. R., Pappas, S. C., Teuber, P., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14052 · Cited by 100
Self-citationNew Developments in Hepatorenal Syndrome
Mindikoglu, A. L., & Pappas, S. C. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.05.041 · Cited by 93
Self-citationEffects of a single terlipressin administration on cardiac function and perfusion in cirrhosis
Krag, A. A., Bendtsen, F., Mortensen, C., Henriksen, J. H., & Møller, S. (2010) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32833a4822 · Cited by 90
Renal dysfunction in cirrhosis is not just a vasomotor nephropathy
Adebayo, D., Morabito, V., Davenport, A., & Jalan, R. (2014) · Kidney International · doi:10.1038/ki.2014.338 · Cited by 88
Terlipressin versus other vasoactive drugs for hepatorenal syndrome
Israelsen, M. E., Krag, A. A., Allegretti, A. S., Jovani, M., Goldin, A. H., Winter, R. W., & Gluud, L. L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011532.pub2 · Cited by 80
Mukhtar, A. M., Salah, M., Aboulfetouh, F., Obayah, G. M., Samy, M. M., Hassanien, A., Bahaa, M. M., Abdelaal, A., Fathy, M., Saeed, H., et al. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e3182120842 · Cited by 76
Wong, F. S.-H., Pappas, S. C., BOYER, T. D., Sanyal, A. J., Bajaj, J. S., Escalante, S., & Jamil, K. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.07.016 · Cited by 66
Self-citationRenal Function in Cirrhosis: A Critical Review of Available Tools
Piano, S. S., Brocca, A., & Angeli, P. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1661372 · Cited by 49
Cited by
Diagnosis and Management of Cirrhosis and Its Complications: A Review
Tapper, E. B., & Parikh, N. D. (2023) · JAMA · doi:10.1001/jama.2023.5997 · Cited by 392
Metadata
- Authors
- Wong, F., Pappas, S. C., Curry, M. P., Reddy, K. R., Rubin, R. A., Porayko, M. K., Gonzalez, S. A., Mumtaz, K., Lim, N., Simonetto, D. A., Sharma, P., Sanyal, A. J., Mayo, M. J., Frederick, R. T., Escalante, S., & Jamil, K.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-03-04
- Volume
- 384
- Issue
- 9
- Pages
- 818-828
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3135382597
- Cited by
- 482
- References
- 21
- FWCI
- 38.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.